EMX Receives Court Approval For Arrangement With Elemental Altus
Elemental Altus has filed an application to list its common shares on the Nasdaq Capital Market (" Nasdaq ") under the ticker symbol "ELE". Due to the ongoing United States federal government shutdown, which presently includes the U.S. Securities and Exchange Commission (" SEC "), the Nasdaq has advised that it cannot further advance the listing application until such time as the SEC reopens to complete its review. EMX and Elemental Altus currently expect that the Nasdaq approval of Elemental Altus's listing application should be forthcoming following the end of the government shutdown and reopening of the SEC and completion of its review process. Until trading commences on the Nasdaq, Elemental Altus's common shares will continue to trade on the TSX Venture Exchange under the ticker symbol "ELE" and on the OTCQX Best Market under the ticker symbol "ELEMF".
Subject to obtaining all required approvals and the satisfaction or waiver of all required conditions, the Arrangement is expected to close by mid-November 2025. Following closing of the Arrangement, the EMX shares are expected to be de-listed from the TSX Venture Exchange, NYSE American Exchange and Frankfurt Stock Exchange (the " De-Listing "). Following the De-Listing, it is anticipated that EMX will apply to cease to be a reporting issuer under applicable Canadian securities laws.
For a more detailed description of the Arrangement, please refer to EMX's management information circular dated September 29, 2025, available under the Company's profile on SEDAR+ at and on EDGAR at , and on the Company's website at .
On Behalf of EMX
David Cole
CEO
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment